APA (7th ed.) Citation

M, F. O., G, V., S, S., L, T., A, Y. D., A, M. I., . . . Krop, I. (2021). Impact of HER2 Heterogeneity on Treatment Response of Early-Stage HER2-Positive Breast Cancer: Phase II Neoadjuvant Clinical Trial of T-DM1 Combined with Pertuzumab. https://doi.org/10.1158/2159-8290.CD-20-1557

Chicago Style (17th ed.) Citation

M, Filho O., et al. Impact of HER2 Heterogeneity on Treatment Response of Early-Stage HER2-Positive Breast Cancer: Phase II Neoadjuvant Clinical Trial of T-DM1 Combined with Pertuzumab. 2021. https://doi.org/10.1158/2159-8290.CD-20-1557.

MLA (9th ed.) Citation

M, Filho O., et al. Impact of HER2 Heterogeneity on Treatment Response of Early-Stage HER2-Positive Breast Cancer: Phase II Neoadjuvant Clinical Trial of T-DM1 Combined with Pertuzumab. 2021. https://doi.org/10.1158/2159-8290.CD-20-1557.